Do analysts rate MOR or REPL?

Replimune Group has a consensus price target of $4.88, suggesting a potential downside of 51.15%. Given Replimune Group's stronger consensus rating and higher probable upside, analysts plainly believe Replimune Group is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Replimune Group 3 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.70

Is MOR or REPL more profitable?

Replimune Group has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Replimune Group's return on equity of -102.69% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Replimune Group N/A -102.69% -72.22%

Does the media prefer MOR or REPL?

In the previous week, Replimune Group had 21 more articles in the media than MorphoSys. MarketBeat recorded 22 mentions for Replimune Group and 1 mentions for MorphoSys. Replimune Group's average media sentiment score of 0.39 beat MorphoSys' score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Replimune Group 3 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has higher earnings and valuation, REPL or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$247.30M -$3.44 N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is REPL or GPCR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -102.69% -72.22% Structure Therapeutics N/A -24.91% -23.67%

Which has higher valuation & earnings, REPL or ALMS?

Alumis has higher revenue and earnings than Replimune Group. Alumis is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$247.30M -$3.44 N/A Alumis $24.05M 106.44 -$243.32M -$1.98 N/A

Is REPL or ALMS more profitable?

Replimune Group has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -102.69% -72.22% Alumis -2,825.70% -88.79% -70.72%

Does the media refer more to REPL or ALMS?

In the previous week, Replimune Group had 20 more articles in the media than Alumis. MarketBeat recorded 22 mentions for Replimune Group and 2 mentions for Alumis. Alumis' average media sentiment score of 1.45 beat Replimune Group's score of 0.39 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Alumis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or REPL more profitable?

Relay Therapeutics' return on equity of -43.94% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Replimune Group N/A -102.69% -72.22%

Does the media prefer RLAY or REPL?

In the previous week, Replimune Group had 16 more articles in the media than Relay Therapeutics. MarketBeat recorded 22 mentions for Replimune Group and 6 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.50 beat Replimune Group's score of 0.39 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 3 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer ARQT or REPL?

In the previous week, Replimune Group had 17 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 22 mentions for Replimune Group and 5 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Replimune Group's score of 0.39 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 3 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral

Replimune Group (REPL) Competitors

$9.98 +1.11 (+12.51%)

Closing price 04:00 PM Eastern

Extended Trading

$9.89 -0.09 (-0.89%)

As of 07:59 PM Eastern

Compare

REPL vs. MOR, GPCR, ALMS, RLAY, and ARQT

Should you buy Replimune Group stock or one of its competitors? MarketBeat compares Replimune Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Replimune Group include MorphoSys (MOR), Structure Therapeutics (GPCR), Alumis (ALMS), Relay Therapeutics (RLAY), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry.

How does Replimune Group compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Replimune Group has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Replimune Group's return on equity of -102.69% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Replimune Group	N/A	-102.69%	-72.22%

In the previous week, Replimune Group had 21 more articles in the media than MorphoSys. MarketBeat recorded 22 mentions for Replimune Group and 1 mentions for MorphoSys. Replimune Group's average media sentiment score of 0.39 beat MorphoSys' score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MorphoSys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Replimune Group	3 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 5.2% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MorphoSys has higher revenue and earnings than Replimune Group. MorphoSys is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

Replimune Group has a consensus price target of $4.88, suggesting a potential downside of 51.15%. Given Replimune Group's stronger consensus rating and higher probable upside, analysts plainly believe Replimune Group is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Summary

Replimune Group beats MorphoSys on 10 of the 14 factors compared between the two stocks.

How does Replimune Group compare to Structure Therapeutics?

Replimune Group (NASDAQ:REPL) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Structure Therapeutics' return on equity of -24.91% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-102.69%	-72.22%
Structure Therapeutics	N/A	-24.91%	-23.67%

In the previous week, Replimune Group had 21 more articles in the media than Structure Therapeutics. MarketBeat recorded 22 mentions for Replimune Group and 1 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Replimune Group's score of 0.39 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Replimune Group	Neutral
Structure Therapeutics	Very Positive

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Replimune Group currently has a consensus price target of $4.88, indicating a potential downside of 51.15%. Structure Therapeutics has a consensus price target of $109.25, indicating a potential upside of 190.95%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Replimune Group has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, suggesting that its share price is 235% less volatile than the broader market.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Summary

Structure Therapeutics beats Replimune Group on 10 of the 14 factors compared between the two stocks.

How does Replimune Group compare to Alumis?

Replimune Group (NASDAQ:REPL) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Replimune Group currently has a consensus target price of $4.88, indicating a potential downside of 51.15%. Alumis has a consensus target price of $40.30, indicating a potential upside of 100.70%. Given Alumis' stronger consensus rating and higher possible upside, analysts plainly believe Alumis is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Replimune Group has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-102.69%	-72.22%
Alumis	-2,825.70%	-88.79%	-70.72%

In the previous week, Replimune Group had 20 more articles in the media than Alumis. MarketBeat recorded 22 mentions for Replimune Group and 2 mentions for Alumis. Alumis' average media sentiment score of 1.45 beat Replimune Group's score of 0.39 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	3 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis has higher revenue and earnings than Replimune Group. Alumis is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A
Alumis	$24.05M	106.44	-$243.32M	-$1.98	N/A

92.5% of Replimune Group shares are held by institutional investors. 5.2% of Replimune Group shares are held by insiders. Comparatively, 33.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Replimune Group has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Alumis has a beta of -0.56, meaning that its stock price is 156% less volatile than the broader market.

Summary

Alumis beats Replimune Group on 11 of the 16 factors compared between the two stocks.

How does Replimune Group compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Relay Therapeutics currently has a consensus price target of $23.30, indicating a potential upside of 52.29%. Replimune Group has a consensus price target of $4.88, indicating a potential downside of 51.15%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70

Replimune Group has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	190.97	-$276.48M	-$1.57	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Relay Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Relay Therapeutics' return on equity of -43.94% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Replimune Group	N/A	-102.69%	-72.22%

In the previous week, Replimune Group had 16 more articles in the media than Relay Therapeutics. MarketBeat recorded 22 mentions for Replimune Group and 6 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.50 beat Replimune Group's score of 0.39 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	3 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Relay Therapeutics beats Replimune Group on 11 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

92.5% of Replimune Group shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 5.2% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Arcutis Biotherapeutics presently has a consensus target price of $34.00, indicating a potential upside of 59.25%. Replimune Group has a consensus target price of $4.88, indicating a potential downside of 51.15%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Arcutis Biotherapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70

Replimune Group has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Replimune Group	N/A	-102.69%	-72.22%

In the previous week, Replimune Group had 17 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 22 mentions for Replimune Group and 5 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Replimune Group's score of 0.39 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	3 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Arcutis Biotherapeutics has higher revenue and earnings than Replimune Group. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.10	-$16.14M	-$0.03	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

Summary

Arcutis Biotherapeutics beats Replimune Group on 11 of the 15 factors compared between the two stocks.

Get Replimune Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REPL vs. The Competition

Export

Metric	Replimune Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$732.42M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-2.90	9.91	18.89	22.53
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	1.85	6.63	9.84	6.72
Net Income	-$247.30M	$24.20M	$3.57B	$337.19M
7 Day Performance	112.34%	-3.24%	-1.16%	0.48%
1 Month Performance	299.20%	0.53%	3.85%	5.07%
1 Year Performance	3.63%	47.24%	27.40%	34.25%

Replimune Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REPL Replimune Group	1.4013 of 5 stars	$9.98 +12.5%	$4.88 -51.2%	-7.3%	$732.42M	N/A	N/A	210	Upcoming Earnings Analyst Forecast
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
GPCR Structure Therapeutics	3.2645 of 5 stars	$39.73 -1.1%	$109.25 +175.0%	+70.7%	$2.82B	N/A	N/A	136
ALMS Alumis	2.9407 of 5 stars	$21.28 -0.6%	$40.30 +89.4%	+509.1%	$2.71B	$24.05M	N/A	N/A	Positive News
RLAY Relay Therapeutics	2.5023 of 5 stars	$14.02 +0.9%	$23.30 +66.2%	+393.7%	$2.69B	$15.35M	N/A	330	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REPL) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Replimune Group (REPL) Competitors

REPL vs. MOR, GPCR, ALMS, RLAY, and ARQT

How does Replimune Group compare to MorphoSys?

Summary

How does Replimune Group compare to Structure Therapeutics?

Summary

How does Replimune Group compare to Alumis?

Summary

How does Replimune Group compare to Relay Therapeutics?

Summary

How does Replimune Group compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Replimune Group (REPL) Competitors

REPL vs. MOR, GPCR, ALMS, RLAY, and ARQT

How does Replimune Group compare to MorphoSys?

Is MOR or REPL more profitable?

Does the media prefer MOR or REPL?

Do insiders and institutionals have more ownership in MOR or REPL?

Which has higher earnings & valuation, MOR or REPL?

Do analysts rate MOR or REPL?

Which has more volatility and risk, MOR or REPL?

Summary

How does Replimune Group compare to Structure Therapeutics?

Is REPL or GPCR more profitable?

Does the media prefer REPL or GPCR?

Do institutionals & insiders believe in REPL or GPCR?

Do analysts recommend REPL or GPCR?

Which has more risk and volatility, REPL or GPCR?

Which has higher earnings and valuation, REPL or GPCR?

Summary

How does Replimune Group compare to Alumis?

Do analysts rate REPL or ALMS?

Is REPL or ALMS more profitable?

Does the media refer more to REPL or ALMS?

Which has higher valuation & earnings, REPL or ALMS?

Do institutionals and insiders believe in REPL or ALMS?

Which has more risk and volatility, REPL or ALMS?

Summary

How does Replimune Group compare to Relay Therapeutics?

Do analysts prefer RLAY or REPL?

Which has stronger valuation & earnings, RLAY or REPL?

Do insiders and institutionals have more ownership in RLAY or REPL?

Which has more volatility & risk, RLAY or REPL?

Is RLAY or REPL more profitable?

Does the media prefer RLAY or REPL?

Summary

How does Replimune Group compare to Arcutis Biotherapeutics?

Do insiders & institutionals have more ownership in ARQT or REPL?

Do analysts prefer ARQT or REPL?

Is ARQT or REPL more profitable?

Does the media prefer ARQT or REPL?

Which has more volatility and risk, ARQT or REPL?

Which has higher earnings and valuation, ARQT or REPL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools